COXs x RELA

Last update 08 May 2025

Basic Info

Related Targets

COXsRELA

Drugs associated with COXs x RELA

DL-0309

Target

COXs x RELA

Mechanism

COX inhibitors [+1]

Active Org.

Institute of Materia Medica

Originator Org.

Institute of Materia Medica

Active Indication

Rheumatoid Arthritis

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with COXs x RELA

100 Translational Medicine associated with COXs x RELA

0 Patents (Medical) associated with COXs x RELA

219

Literatures (Medical) associated with COXs x RELA

01 Aug 2025·Journal of Pharmaceutical and Biomedical Analysis

Yi-qi-yang-yin decoction ameliorates diabetic retinopathy: New and comprehensive evidence from network pharmacology, machine learning, molecular docking and molecular biology experiment

Article

Author: Kong, De-Xing ; Shen, Qing ; Huang, De-Lian ; Tong, Yu-Hua ; Zeng, Xi-Xi ; Gao, Yuan ; Liu, Shi-Yu ; Li, Ping ; Wang, Si-Wei ; Hu, Yan-Jun ; Lan, Tian ; Mao, Zhu-Jun

Yi-Qi-Yang-Yin Decoction (YQYY), a traditional Chinese medicine (TCM) formula, has been used to treat diabetic retinopathy (DR), yet its precise mechanisms of action remain poorly understood. In this study, two distinct diabetic models, namely spontaneous type 2 diabetic db/db mice and streptozotocin (STZ)-induced type 1 diabetic rats, were employed to assess the efficacy of YQYY in ameliorating DR. Ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) was employed to identify the chemical composition of YQYY in mouse serum. Next, the possible targets and key pathways of YQYY for the management of DR were predicted by integrating network pharmacology and weighted gene co-expression network analysis (WGCNA). Network-based indicators were then employed to evaluate the efficacy of the formulae on DR, and molecular docking, along with compound similarity analysis, was used to identify candidate drugs of YQYY for DR. Finally, molecular biology techniques were utilized to experimentally validate the identified targets. Experimental results from animal models showed that YQYY effectively improved hemoglobin A1C (HbA1C), reduced vessel branch points, and mitigated retinal tissue injury in both DR models. 17 herbal components were identified in the YQYY-containing serum by UPLC-QTOF-MS. Network pharmacology predicted 44 common targets of YQYY involved in the regulation of DR. These targets were found to mainly participate in inflammation-related signaling pathways, including the NF-κB signaling pathway, toll-like receptor signaling pathway, IL-17 signaling pathway, and TNF signaling pathway. By integrating the most relevant disease templates for DR with network pharmacology, we preliminarily identified two key functions of YQYY and their associated regulatory targets, which showed strong connections and correlations with the targets identified in the screened DR disease models. These results demonstrate the pivotal role of core targets, such as BAX, BCL2, MMP9, SIRT1, PPARγ, VCAM1, PTGS2, TNF-α, and RELA, in mediating the therapeutic effects of YQYY in managing DR. Network analysis of YQYY efficacy in DR revealed a significant correlation between the YQYY targets and DR-related genes. Furthermore, molecular docking and drug similarity comparisons suggested that kaempferol, formononetin, and caffeic acid show potential as therapeutic candidates for DR. Our investigation demonstrated the therapeutic efficacy of YQYY against DR, shedding light on novel perspectives regarding the active constituents and molecular pathways through which YQYY exerts its effects in managing DR.

01 Apr 2025·Planta Medica

Combating Inflammation and Oxidative Stress: Exploring the Cellular Effects of Lonicera caerulea var. kamtschatica Extract

Article

Author: Khaidakov, Barbara ; Banaszkiewicz, Laura ; Zima, Katarzyna ; Kowalczyk, Paulina ; Lemke, Krzysztof ; Woźniak, Mateusz Kacper

Abstract Lonicera caerulea var. kamtschatica, known as blue honeysuckle or haskap berry, is rich in bioactive compounds such as polyphenols, flavonoids, and anthocyanins, which are linked to various health benefits, including anti-inflammatory and antioxidant properties. The research specifically investigates the effects of an L. caerulea var. kamtschatica extract that has been standardized to contain a minimum of 15% anthocyanins on inflammation and oxidative stress at the cellular level. In vitro studies using A549 human lung epithelial cells and peripheral blood mononuclear cells demonstrated the extractʼs anti-inflammatory and antioxidant properties. L. caerulea var. kamtschatica extract significantly inhibited the nuclear translocation of NF-κB p65 and reduced the production of IL-8 in A549 cells. It also downregulated the expression of proinflammatory genes (RELA and PTGS2) while upregulating antioxidant genes (CAT, HMOX1, and SOD2). In peripheral blood mononuclear cells, L. caerulea var. kamtschatica extract decreased the phosphorylation of NF-κB p65 and reduced the levels of proinflammatory cytokines IL-1β and IL-6 following lipopolysaccharide stimulation. Additionally, the extract inhibited reactive oxygen species formation and nitric oxide production, demonstrating its potential to modulate oxidative stress. Furthermore, in vitro assays indicated that L. caerulea var. kamtschatica extract could hinder the binding of SARS-CoV-2 spike protein to the hACE2 receptor, suggesting antiviral potential.These findings suggest that L. caerulea var. kamtschatica extract exerts significant anti-inflammatory and antioxidant effects, indicating its potential as a functional food ingredient or dietary supplement to combat inflammation and oxidative stress.

01 Feb 2025·Journal of Molecular Histology

MiRNAs and tempol therapeutic potential in prostate cancer: a preclinical approach

Article

Author: Rossetto, Isabela Maria Urra ; Cagnon, Valéria H A ; Marson, Leonardo A ; Montico, Fábio ; Alves, Letícia F ; Santos, Felipe R ; Geraldo, Murilo V

This study investigated tempol action on genes and miRNAs related to NFκB pathway in androgen dependent or independent cell lines and in TRAMP model in the early and late-stages of cancer progression. A bioinformatic search was conducted to select the miRNAs to be measured based on the genes of interest from NFκB pathway. The miR-let-7c-5p, miR-26a-5p and miR-155-5p and five target genes (BCL2, BCL2L1, RELA, TNF, PTGS2) were chosen for RT-PCR and gene enrichment analyses. In vitro, PC-3 and LNCaP cells were exposed, respectively, to 1.0 or 2.0 mM of tempol during 48 h. In vivo, five experimental groups were evaluated regarding tempol effects in the early (CT12 and TPL12 groups) and late-stages (CT20, TPL20-I and TLP20-II) of PCa development. TPL groups were treated with 50 mg/kg or 100 mg/kg of tempol. The ventral lobe of the prostate and the plasma was collected. Tempol treatment increased miRs expression in PC-3 and LNCaP. For both cell lines, tempol decreased RELA expression. In TRAMP model, tempol increased miRNA expression in prostate for all treated groups. Tempol upregulated the miRNA expressions related to the NFκB pathway in the prostate tissue and human tumor cell lines. Their increase is mainly linked to increased cell death and delayed CaP aggressivenes. Thus, tempol's capacity for miRNA-mediated gene silencing to decrease tissue proliferation and cell survival processes is part of its tissue mechanics.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis